{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:10:09Z","timestamp":1791259809696,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.semarthrit.2024.152560","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T12:03:25Z","timestamp":1727179405000},"page":"152560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study"],"prefix":"10.1016","volume":"69","author":[{"given":"Edoardo","family":"Conticini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-2882","authenticated-orcid":false,"given":"Paolo","family":"Cameli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Grazzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriana","family":"d'Alessandro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bergantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunetta","family":"Porcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Mazzei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Frediani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152560_bib0001","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845988","article-title":"Different multivariable risk factors for rapid progressive interstitial lung disease in anti-MDA5 positive dermatomyositis and anti-synthetase syndrome","volume":"13","author":"Zuo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0003","doi-asserted-by":"crossref","first-page":"E25816","DOI":"10.1097\/MD.0000000000025816","article-title":"Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies","volume":"100","author":"Jiang","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0004","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study","volume":"40","author":"Bozzalla-Cassione","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8112013","article-title":"Influence of Antisynthetase antibodies specificities on antisynthetase syndrome clinical spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0006","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kem045","article-title":"Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia","volume":"46","author":"Betteridge","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0007","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s12026-023-09387-z","article-title":"Prevalence of myositis specific and associated antibodies in a cohort of patients affected by idiopathic NSIP and no hint of inflammatory myopathies","volume":"71","author":"Conticini","year":"2023","journal-title":"Immunol Res"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0008","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0009","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0010","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1183\/16000617.00002015","article-title":"Idiopathic inflammatory myopathies and the lung","volume":"24","author":"Lega","year":"2015","journal-title":"Eur Respir Rev"},{"issue":"134","key":"10.1016\/j.semarthrit.2024.152560_bib0011","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study","volume":"40","author":"Bozzalla-Cassione","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0012","first-page":"151","article-title":"Tocilizumab Vs methotrexate in a cohort of patients affected by active GCA: a comparative clinical and ultrasonographic study","volume":"17","author":"Grazzini","year":"2023","journal-title":"Biologics"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0013","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0014","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0015","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3899\/jrheum.091402","article-title":"Anticyclic citrullinated peptide antibodies as markers of erosive arthritis in antisynthetase syndrome","volume":"37","author":"Cavagna","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0016","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0017","first-page":"44","article-title":"Timing of onset affects arthritis presentation pattern in antisynthetase syndrome","volume":"36","author":"Gonz\u00e1lez-Gay","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0018","doi-asserted-by":"crossref","first-page":"II10","DOI":"10.1093\/rap\/rkab054","article-title":"Clinical profile and treatment outcomes in antisynthetase syndrome: a tertiary centre experience","volume":"5","author":"Sreevilasan","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0019","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s40674-020-00139-w","article-title":"Update on treatment of antisynthetase syndrome: a brief review","volume":"6","author":"Zanframundo","year":"2020","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0021","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kew146","article-title":"Rituximab in the treatment of inflammatory myopathies: a review","volume":"56","author":"Fasano","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0022","first-page":"858","article-title":"Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome","volume":"37","author":"Casal-Dominguez","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0023","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00296-023-05302-9","article-title":"Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease","volume":"43","author":"Zeki\u0107","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0024","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1007\/s10067-021-05590-1","article-title":"Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort","volume":"40","author":"Nair","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0025","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0026","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s00296-023-05302-9","article-title":"Rituximab as the first-line therapy in anti-synthetase syndrome-related interstitial lung disease","volume":"43","author":"Zeki\u0107","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0027","first-page":"285","article-title":"Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study","volume":"41","author":"Conticini","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0028","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0029","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0030","article-title":"Review: idiopathic inflammatory myopathies: state of the art on clinical practice guidelines","volume":"4","author":"Meyer","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0031","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0032","doi-asserted-by":"crossref","first-page":"E23677","DOI":"10.1097\/MD.0000000000023677","article-title":"Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u2018ProDERM Study\u2019)","volume":"100","author":"Aggarwal","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103264","article-title":"The role of bDMARDs in idiopathic inflammatory myopathies: a systematic literature review","volume":"22","author":"Grazzini","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0034","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3899\/jrheum.121026","article-title":"Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease","volume":"40","author":"Cavagna","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0035","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152560_bib0036","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224002002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224002002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T15:53:00Z","timestamp":1732636380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224002002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"alternative-id":["S0049017224002002"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152560","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152560","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152560"}}